Progen Industries Ltd (PGLAF) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Progen Industries Ltd (PGLAF)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Henrik	9/20/2007 6:10:09 PM
	of 349

Orphan Drug Designation for PI-88 granted in the EU Brisbane, Australia. 20 September 2007: Progen Pharmaceuticals Limited (ASX: PGL; NASDAQ: PGLA) today announced that the Commission of the European Communities has granted orphan product designation for PI-88 for the treatment of hepatocellular carcinoma, or primary liver cancer. This follows the positive recommendation received in August, from the European Agency for the Evaluation of Medicinal Products (EMEA) Committee for Orphan Medical Products for PI-88 in this indication.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next